despit
convent
manag
antibiot
respiratori
physiotherapi
pulmonari
function
undergo
steadi
declin
cystic
fibrosi
cf
pulmonari
exacerb
pex
import
clinic
outcom
cf
associ
faster
rate
declin
forc
expiratori
volum
fev
increas
morbid
mortal
patient
cf
almost
patient
fail
recov
baselin
fev
pex
reason
patient
fail
recov
previou
fev
appropri
treatment
fulli
understood
even
though
risk
factor
identifi
pancreat
insuffici
low
bodi
mass
index
bmi
chronic
infect
cf
pathogen
greater
drop
fev
baselin
treatment
initi
virus
frequent
trigger
pex
rhinovirus
frequent
viral
agent
found
patient
cf
impair
innat
host
defens
may
caus
increas
suscept
viral
respiratori
infect
patient
cf
sever
viral
infect
might
respons
exagger
pulmonari
inflammatori
respons
howev
literatur
pauciti
data
regard
pex
outcom
cf
children
concomit
viral
respiratori
infect
infect
seem
play
signific
role
pulmonari
morbid
inflamm
patient
cf
inde
patient
present
concomit
bacteri
viral
infect
show
greater
rate
hospit
antibiot
prescript
unfortun
consequ
viral
respiratori
infect
evolut
cf
lung
diseas
hard
studi
larg
scale
order
evalu
issu
close
longitudin
followup
repeat
viral
swab
assess
need
could
therefor
specul
impact
respiratori
virus
probabl
underestim
patient
cf
hypothes
respiratori
virus
major
risk
factor
maintain
extend
bronchial
inflamm
pex
recoveri
period
aim
studi
determin
associ
viralassoci
pex
failur
improv
fev
pex
treatment
cf
children
pediatr
pilot
studi
conduct
januari
march
cf
center
montpelli
reim
franc
patient
age
year
recruit
pex
defin
accord
european
respiratori
societi
criteria
chang
respiratori
statu
requir
antibiot
treatment
cluster
symptom
indic
eurocarecf
work
group
studi
eudract
approv
local
ethic
committe
ref
children
parent
sign
consent
form
patient
longitudin
assess
three
time
cf
univers
center
baselin
visit
diagnosi
pex
visit
pex
treatment
visit
schedul
week
begin
pex
treatment
shown
antibiot
respons
exacerb
assess
pft
essenti
complet
week
treatment
initi
clinician
work
cf
univers
center
manag
pex
accord
guidelin
clinic
data
pft
record
visit
sampl
upper
lower
airway
collect
two
nasal
swab
two
spontan
expector
sputa
visit
viral
bacteri
analysi
viral
analysi
perform
commerci
multiplex
pcr
assay
seegen
provid
qualit
detect
virus
without
genotyp
human
adenoviru
influenza
b
viru
human
parainfluenza
viru
human
rhinoviru
human
respiratori
syncyti
viru
b
human
bocaviru
human
coronaviru
human
metapneumoviru
human
enteroviru
clinician
blind
result
virolog
test
end
studi
particip
categor
rel
chang
fev
predict
visit
visit
calcul
follow
fev
predict
visit
predict
visit
fev
predict
visit
respond
fev
improv
nonrespond
fev
improv
pex
treatment
threshold
previous
use
mani
studi
quantit
variabl
express
mean
standard
deviat
compar
use
wilcoxon
test
appropri
qualit
variabl
express
number
absolut
number
compar
use
chisquar
test
fisher
test
appropri
logist
regress
use
estim
ci
present
studi
patient
includ
montpelli
center
reim
center
among
patient
complet
visit
analyz
patient
lost
follow
go
exacerb
period
studi
eight
patient
classifi
respond
patient
nonrespond
pex
treatment
patient
characterist
similar
two
group
tabl
patient
present
sever
associ
comorbid
none
diabet
one
patient
undernourish
one
patient
fev
baselin
delay
vari
day
median
delay
day
without
differ
two
group
tabl
nonrespond
group
significantli
viral
respiratori
infect
andor
versu
p
rhinoviru
respiratori
infect
andor
versu
p
tabl
visit
detect
virus
nasal
swab
expector
sputa
nasal
bronchial
swab
concord
visit
proport
viral
respiratori
infect
diagnosi
pex
baselin
rhinovirus
account
identifi
virus
detect
viral
coinfect
one
patient
rhinoviru
metapneumoviru
influenza
viru
vaccin
record
patient
pex
occur
specif
respiratori
virus
epidem
spread
specif
season
risk
factor
significantli
associ
failur
improv
fev
pex
viral
respiratori
infect
andor
ci
p
especi
rhinoviru
infect
ci
p
factor
pancreat
insuffici
atop
statu
bmi
baselin
treatment
azithromycin
inhal
corticosteroid
therapi
antibiot
therapi
persist
infect
pseudomona
aeruginosa
staphylococcu
aureu
detect
new
bacteria
pathogen
includ
bacteria
speci
spirometr
paramet
ie
fev
drop
therapeut
featur
ie
adapt
pex
antibiotherapi
accord
ecf
guidelin
intraven
treatment
durat
antibiot
treatment
significantli
associ
failur
improv
fev
pex
treatment
tabl
nonrespond
patient
fail
significantli
improv
forc
vital
capac
fvc
ci
p
tabl
rhinoviru
respiratori
infect
significantli
associ
failur
improv
fvc
pex
treatment
adjust
ci
p
result
pilot
studi
show
rhinoviru
infect
pex
significantli
associ
failur
improv
fev
pex
treatment
children
cf
none
subject
new
symptom
pulmonari
exacerb
third
visit
think
nonrespond
children
sick
failur
recoveri
might
consequ
exacerb
diagnos
second
visit
knowledg
one
studi
assess
relationship
respiratori
virus
sampl
bronchoscopi
pft
result
pex
treatment
cf
pediatr
patient
observ
strong
associ
respiratori
virus
newli
acquir
common
respiratori
pathogen
wors
recoveri
month
follow
bronchoscopi
patient
infect
respiratori
virus
perform
complet
noninvas
assess
viral
respiratori
infect
upper
lower
airway
method
use
collect
specimen
viral
analysi
neg
nasal
swab
posit
sputum
viru
mainli
rhinovirus
associ
asthma
exacerb
studi
one
patient
asthma
treat
inhal
corticotherapi
main
limit
studi
includ
small
number
patient
could
design
fourth
visit
later
follow
nonrespond
children
moreov
microbiolog
analysi
exhaust
atyp
mycobacteria
anaerob
bacteria
fungi
investig
studi
show
upper
airway
rhinovirusassoci
clinic
symptom
like
result
local
system
immun
respons
consequ
direct
cytopathogen
effect
nevertheless
pathophysiolog
rhinovirusassoci
pex
remain
unclear
cf
two
recent
studi
show
exagger
bronchial
inflamm
associ
rhinoviru
infect
airway
epitheli
cell
patient
cf
largescal
analys
requir
studi
impact
rhinovirus
failur
recov
previou
fev
level
cf
children
